A Clinical Study to Assess Safety, Efficacy and In-use Tolerability of Different Dosages of Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).
Prospective, Interventional, Exploratory, Four-Arm - Dose Response Study, Comparative, Double-Blind, Randomized, Placebo-Control, Proof of Concept, Safety, Efficacy and In-Use Tolerability Study of Three Different Dosage Formulation of Test Hair Growth Products and Placebo in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- NovoBliss Research Pvt Ltd
- Participants (registry)
- 72
- Start
- September 2024
- Primary completion
- June 2025
- Study completion
- July 2025
- Last registry update
- July 2026
- Countries
- India
Conditions studied: Androgenic Alopecia
Interventions: SesZen-Bio Low Dose 1 (350 mg extract), SesZen-Bio Low Dose 1 (150 mg liposomal), SesZen-Bio High Dose 1 (500 mg extract), Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.